You are here

Our science / Clinical Trials / Find a Trial / NCT00367887

A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects

Back to Search Print Save as PDF Bookmark Trial

NCT00367887

Last updated on February 22, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Anaheim, California, 92801 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hepatitis C
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Infection with HCV genotype 1.

- HCV- infected subjects naive to treatment.

- HCV-infected non-responder subjects.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Women who are pregnant or breastfeeding.

- ALT >/ or = 5X the upper limit of normal.

- AST >/ or = 5X the upper limit of normal.

NCT00367887
Pfizer
Completed
A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Chronic Hepatitis C
Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance
NCT01210404
All Genders
18+
Years
Multiple Sites
HIV Infection, Hepatitis C
An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C
NCT00141284
All Genders
18+
Years
Multiple Sites
Chronic Hepatitis C
Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes
NCT01226797
All Genders
18+
Years
Multiple Sites
Hepatitis C Virus
Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State
NCT00861458
All Genders
18+
Years
Bruxelles,

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now